Hydrea

Ovarian Neoplasms, Thrombocythemia, Essential, Anemia, Sickle Cell + 4 more
Treatment
2 FDA approvals
20 Active Studies for Hydrea

What is Hydrea

HydroxyureaThe Generic name of this drug
Treatment SummaryA medication used to inhibit the growth and spread of cancer cells by blocking the production of DNA in the cells.
Hydroxyureais the brand name
image of different drug pills on a surface
Hydrea Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hydroxyurea
Hydroxyurea
1998
25

Approved as Treatment by the FDA

Hydroxyurea, also known as Hydroxyurea, is approved by the FDA for 2 uses which include inoperable Ovarian cancer and Ovarian Neoplasms .
inoperable Ovarian cancer
Ovarian Neoplasms

Effectiveness

How Hydrea Affects PatientsWhen taken together, hydroxyurea and cisplatin have been shown to be effective against certain types of human lung cancer in both lab and animal studies. The greatest effect is seen when hydroxyurea is taken 4 hours before cisplatin.
How Hydrea works in the bodyHydroxyurea works by converting into a free radical and entering cells where it stops a protein from working. This protein is needed for cells to replicate, so blocking it prevents cells from reproducing. Hydroxyurea also helps repair damaged DNA, making it more effective when combined with radiation or chemicals. Lastly, it increases the amount of fetal hemoglobin in sickle cell anemia, reducing the risk of dangerous blockages.

When to interrupt dosage

The measure of Hydrea is contingent upon the diagnosed ailment, including Myeloid Leukemia, Hypereosinophilic Syndrome (HES) and Thrombocythemia, Essential. The dosage likewise fluctuates as per the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Thrombocythemia, Essential
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Sickle Cell Crisis
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Polycythemia Vera
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Hypereosinophilic Syndrome
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Ovarian Neoplasms
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Anemia, Sickle Cell
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral
Meningioma
500.0 mg, , 1000.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 400.0 mg, 100.0 mg/mL
Capsule, , Oral, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral

Warnings

There are 20 known major drug interactions with Hydrea.
Common Hydrea Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Acteoside.
Hydrea Toxicity & Overdose RiskThe lethal dose in mice is 7330mg/kg and in rats is 5760mg/kg. Animal studies have shown that hydroxyurea may cause birth defects. There have also been reports of humans using hydroxyurea during pregnancy without any adverse effects. Additionally, animal and human studies have suggested that hydroxyurea may cause mutations.
image of a doctor in a lab doing drug, clinical research

Hydrea Novel Uses: Which Conditions Have a Clinical Trial Featuring Hydrea?

63 active studies are being conducted to assess the effectiveness of Hydrea in treating Myeloid Leukemia, Polycythemia Vera (PV) and inoperable Ovarian Cancer.
Condition
Clinical Trials
Trial Phases
Thrombocythemia, Essential
25 Actively Recruiting
Phase 2, Phase 1, Phase 3
Sickle Cell Crisis
1 Actively Recruiting
Not Applicable
Anemia, Sickle Cell
1 Actively Recruiting
Not Applicable
Ovarian Neoplasms
0 Actively Recruiting
Hypereosinophilic Syndrome
0 Actively Recruiting
Polycythemia Vera
0 Actively Recruiting
Meningioma
0 Actively Recruiting

Hydrea Reviews: What are patients saying about Hydrea?

5Patient Review
3/30/2014
Hydrea for Increased Red Blood Cells
I've been taking this medication for 8 years to treat pv/mf. Recently, I've been having severe eye problems and upper gut issues including bloating and digestive disorders. I might need to cut back on the dosage to figure out what is causing what. Has anyone experienced upper stomach swelling and nausea with headaches?
4.7Patient Review
4/13/2013
Hydrea for Spontaneous Hemorrhages and Increase in Blood Platelets
4Patient Review
7/8/2014
Hydrea for Increased Red Blood Cells
I started feeling nauseous after 10 days of taking Hydrea.
3.7Patient Review
12/1/2013
Hydrea for Increased Red Blood Cells
I'm constantly exhausted and I can't tell if it's the hydrea or my low iron levels. Either way, it's really frustrating because I used to have so much energy.
3.7Patient Review
7/27/2017
Hydrea for Increased Red Blood Cells
I have polycythemia vera, and while this treatment has lowered my numbers, I don't like the side effects. I'm tired all the time, I've lost interest in things I used to enjoy, and my hair is falling out. I wish there was a treatment that didn't make me feel so lousy.
3.3Patient Review
5/3/2015
Hydrea for Increased Red Blood Cells
I felt really tired and sluggish after taking this, almost like I had no energy. Additionally, I experienced constipation.
3Patient Review
6/22/2017
Hydrea for Increased Red Blood Cells
This treatment has been effective in keeping my blood disorder under control for the last six years, but now I have developed cancer in my mouth.
2.3Patient Review
5/24/2015
Hydrea for Type of Leukemia - Chronic Myelogenous Leukemia
I'm already having a lot of negative side effects after only three days on this medication. I have shortness of breath, bad vision, numbness, vomiting, loose bowels, pain, and a dry stomach. I've called the pharmacy and my doctor but no one is answering. I wouldn't recommend this treatment to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about hydrea

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Hydrea?

"These are some of the side effects that may occur. If you experience any of these side effects, speak to your doctor or pharmacist."

Answered by AI

What is Hydrea prescribed for?

"Hydroxyurea is used to prevent painful episodes and reduce the need for blood transfusions in patients with sickle cell anemia by making the red blood cells more flexible."

Answered by AI

Is Hydrea a cancer drug?

"Hydrea is a cancer treatment that works by inhibiting the metabolism of cancer cells. It is approved to treat certain forms of chronic myeloid leukemia and skin cancer."

Answered by AI

How long can someone take Hydrea?

"You can take hydroxyurea for an indefinite amount of time, as long as it is effective.How will you know that hydroxyurea is working? It usually takes a few months for hydroxyurea to start working, so you may not feel any immediate improvement."

Answered by AI

Clinical Trials for Hydrea

Image of City of Hope Comprehensive Cancer Center LAO in Duarte, United States.

ASTX727 + Iadademstat for Myeloproliferative Disorders

18+
All Sexes
Duarte, CA
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.
Phase 2
Recruiting
City of Hope Comprehensive Cancer Center LAO (+7 Sites)Anand A Patel
Image of Ruttenberg Treatment Center in New York, United States.

Methotrexate for Myeloproliferative Disorders

18+
All Sexes
New York, NY
Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If MTX proves to be safe and tolerable with a signal of clinical activity, this could have a significant benefit to patients with MPNs. Beyond the potential benefit of adding a type 2 JAK inhibitor to current therapy, this could signal the need to study MTX in MPNs further as a monotherapy. Discovering MTX as safe and clinically effective in MPNs could be profound on both a public health and global health scale for patients who are uninsured and cannot afford more expensive novel JAK inhibitors, or for those in countries where JAK inhibitors are not available. Accordingly, the research team deems it reasonable and prudent to assess the safety and efficacy of MTX in addition to current therapy for patients with MPN. The research team will evaluate patients for spleen responses, symptom responses, and cytologic responses. Correlative data will evaluate pharmacokinetic and disease modifying activity of MTX in MPNs to inform future clinical trials.
Phase 2
Recruiting
Ruttenberg Treatment CenterJohn Mascarenhas
Have you considered Hydrea clinical trials? We made a collection of clinical trials featuring Hydrea, we think they might fit your search criteria.Go to Trials
Image of University of Michigan ( Site 6000) in Ann Arbor, United States.

Bomedemstat for Blood Disorders

18+
All Sexes
Ann Arbor, MI
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
Phase 3
Recruiting
University of Michigan ( Site 6000) (+3 Sites)Medical DirectorMerck Sharp & Dohme LLC
Have you considered Hydrea clinical trials? We made a collection of clinical trials featuring Hydrea, we think they might fit your search criteria.Go to Trials
Image of Children's Wisconsin in Milwaukee, United States.

Enhanced Emergency Care for Sickle Cell Crisis

< 65
All Sexes
Milwaukee, WI
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.
Recruiting
Has No Placebo
Children's WisconsinDavid Brousseau, MD, MS
Have you considered Hydrea clinical trials? We made a collection of clinical trials featuring Hydrea, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security